Lonza to Partner With Teva on Biosimilars

February 11, 2009
Teva Pharmaceutical Industries and Lonza Group are establishing a joint venture to develop, manufacture and market biosimilars. Both companies plan to explore additional biosimilars opportunities outside the partnership, according to a joint statement. The companies expect to start operations in this year’s first quarter. Financial details of the agreement were not disclosed.
Drug GMP Report